Pharmaceutical company Merck announced Monday that its investigational cancer treatment achieved primary endpoints in advanced clinical testing for patients battling cancer of the uterine lining.
According to the company, the experimental medication sacituzumab tirumotecan demonstrated improved survival outcomes and slowed disease advancement when compared to standard chemotherapy treatments in patients whose endometrial cancer had continued to progress after receiving conventional therapies.
The clinical study included 776 participants diagnosed with advanced or recurring endometrial cancer.
